Verano Holdings (VRNO) Net Income towards Common Stockholders Growth (1y) (2022 - 2026)
Verano Holdings (VRNO) Net Income towards Common Stockholders Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Verano Holdings | 439.55 Mn | 354.35 Mn | 99.70 Mn | 29.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.97% |
| Mar 31, 2026 | -54.78% |
| Dec 31, 2025 | 32.74% |
| Sep 30, 2025 | -2.97% |
| Jun 30, 2025 | 12.01% |
| Mar 31, 2025 | -138.80% |
| Dec 31, 2024 | -252.85% |
| Sep 30, 2024 | -139.63% |
| Jun 30, 2024 | -66.63% |
| Mar 31, 2024 | 47.80% |
| Dec 31, 2023 | 64.24% |
| Sep 30, 2023 | 58.68% |
| Jun 30, 2023 | -32.64% |
| Mar 31, 2023 | -120.14% |
| Dec 31, 2022 | -3,065.98% |
| Sep 30, 2022 | -259.41% |
| Jun 30, 2022 | 66.72% |